Unleashing the Power of Plasmalogen Therapy
Med-Life Discoveries is the leader in the development of pharmaceutical-grade plasmalogen therapies for several conditions including Rhizomelic Chondrodysplasia Punctata (RCDP).*
*MLD’s plasmalogen therapeutics are currently undergoing required formal regulatory safety and efficacy studies and are not currently available to the public.
News
Catch up on our latest whereabouts and milestones here!
News
Peroxisomal Disorders
Rhizomelic Chondrodysplasia Punctata (RCDP) affects fewer than 100 patients in North America. But there is #hopeforRCDP and other plasmalogen-deficient peroxisomal disorders with PPI-1011: a first-in-class plasmalogen therapy in clinical development.
Neurological Conditions
Plasmalogen deficiency is associated with several neurological conditions including Alzheimer’s disease, Parkinson’s disease, and Multiple sclerosis. Therapeutically augmenting plasmalogens represents a new paradigm for the management of these diseases.
Literature
